Renaissance Capital logo

Royalty Pharma Priced, Nasdaq: RPRX

Buys royalty interests in marketed and late-stage biopharmaceuticals.

Industry: Health Care

First Day Return: +58.9%

Industry: Health Care

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, including Imbruvica, Januvia, Kalydeco, Trikafta, Truvada, Tysabri and Xtandi. We fund innovation in the biopharmaceutical industry both directly and indirectly—directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. We believe that our significant scale, flexible business model and extensive expertise uniquely position us to take advantage of the increasing innovation in the biopharmaceutical industry. We seek to create favorable outcomes for all parties and play an important role in providing capital to the biopharmaceutical ecosystem that supports innovation and positively impacts human health.
more less
IPO Data
IPO File Date 05/22/2020
Offer Price $28.00
Price Range $25.00 - $28.00
Offer Shares (mm) 77.7
Deal Size ($mm) $2,175
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/15/2020
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $2,175
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters New York, NY, United States
Founded 1996
Employees at IPO 35
Website www.royaltypharma.com

Royalty Pharma (RPRX) Performance